LICR believes that clinical research in cancer cannot be undertaken as simply product development, but rather requires a systematic, academic approach to develop rational therapeutic strategies in the only setting that really counts – the cancer patient. LICR is one of very few academic organizations, anywhere in the world, that produces its own regulatory-standard therapeutic study agents, and plans, conducts, administers, and sponsors its own clinical trials. This model allows basic investigations to continue into early stage clinical evaluation of a new therapy, making the clinic an essential arm of the research enterprise.

LICR is currently exploring three separate cancer treatment modalities: cancer vaccines and targeted antibodies. These targeted therapies are designed to prevent the growth of tumours and the spread of cancer, without the dangerous and unpleasant side effects of current cancer therapies.